Physician profile
Charusheela Andaz
NPI 1437163235
$4,294.46
in general payments reported to CMS, 2019-2025
12 companies · $1,886 in 2025
The $1,886 reported for 2025 was more than what 81% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2021: $1,300 · 2022: $66.34 · 2023: $525 · 2024: $105 · 2025: $1,886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,438 · Food and Beverage: $1,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,437.68 |
| Food and Beverage | $1,079.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axogen | $1,862.91 | 2025 | |
| Davol INC. | $1,300.00 | 2021 | |
| Molli Surgical (US) INC | $386.90 | 2023 | |
| Focal Therapeutics, INC. | $203.00 | 2019 | |
| Hologic INC | $187.68 | 2019 | |
| Endomagnetics LTD | $116.55 | 2023 | Magseed, Magtrace |
| Roche Diagnostics Corporation | $73.94 | 2024 | |
| Leica Microsystems INC. | $66.34 | 2022 | |
| Kub Technologies INC. | $31.39 | 2024 | |
| Tactile Systems Technology INC | $23.53 | 2025 | Nimbl, Flexitouch Plus |
| Innocoll Pharmaceuticals Limited | $22.03 | 2023 | Xaracoll |
| Abbott Laboratories | $20.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charusheela Andaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.